BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7504543)

  • 1. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM
    Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
    Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
    Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P; Calabretta B
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
    Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
    Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
    Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
    Diamond J; Goldman JM; Melo JV
    Blood; 1995 Apr; 85(8):2171-5. PubMed ID: 7718887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
    Calabretta B; Sims RB; Valtieri M; Caracciolo D; Szczylik C; Venturelli D; Ratajczak M; Beran M; Gewirtz AM
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2351-5. PubMed ID: 2006173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P; Amadori S; Calabretta B; Mandelli F
    Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligodeoxynucleotide-based therapeutics for human leukemias.
    Gewirtz AM
    Stem Cells; 1993 Oct; 11 Suppl 3():96-103. PubMed ID: 7507759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
    Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.